A recent study led by researchers from Massachusetts General Hospital Heart Health (MGHHeartHealth) and the Broad Institute has made significant strides in cardiovascular disease (CVD) prevention. The team developed MSGene, a multistate lifetime risk model for atherosclerotic cardiovascular disease (ASCVD), which uses genetics and dynamic risk factor trajectories to predict the risk of coronary artery disease (CAD) over a person's lifetime. This innovative approach aims to enable earlier and more effective cardiovascular prevention. The study, now published in Nature Communications, highlights the importance of accurate and dynamic estimates of lifetime ASCVD risk. The research team includes notable contributors such as @tigerstatdoc, @pnatarajanmd, and @SashaGusevPosts. Additionally, the study addresses the limitations of the 10-year ASCVD risk prediction model, which often prioritizes older individuals for statins, missing opportunities for earlier risk recognition and prevention.
Important study towards understanding the utility of PGS for CVD primary prevention (here PGS seems to be useful). Not yet an RCT, but nested case-control study. Good step forward while waiting for a big RCT @Genomicsplc leadership among authors, but has not funded the study https://t.co/m1pHd1VZVS
Do polygenic scores (PRS) have a role in cardiovascular risk assessment?🧬 👉In real-world setting, PRS implementation improved detection of high-risk individuals who went on to have CVD🫀 🧐These patients could benefit from tailored risk management💊 https://t.co/laXKZTBlNU https://t.co/9S2jjAWPbZ
Congratulations, Dr. Sergio Aguilar-Fernández! It has been an honour working with you over the last 3 years. This is just the beginning of your superstar science career. Very good luck and fun @villanilab in Boston @broadinstitute @harvardmed @MGHMedicine. https://t.co/XnjyHMS5dW
Huge congrats @BellomoTiffany! Very excited to have you in the lab! @MGHHeartHealth @MGHVascular @broadinstitute And thank you @nih_nhlbi! 🎉🎉 https://t.co/h594tJwNbY
Thrilled 🎉 that my F32 application to study the “Genetics of carotid artery disease progression…” was selected for funding by the NHLBI. I have immense gratitude for the unwavering mentorship provided by my entire F32 team, especially @pnatarajanmd and Dr. Eagleton!
I successfully defended my PhD Thesis today at @YaleIBIO!!!! Such an honor to share one of three projects I've pursued during my time in the Iwasaki (@VirusesImmunity) Lab! Thank you to all my friends, family, and mentors for their support today! #PhD #MDPhDToBe https://t.co/fGJ9Xow2Ca
As of Sept. 1, I will be promoted to ASSOCIATE Professor with Tenure!! Thanks to all my collaborators, mentors, and mentees who have played a part in my career. Can’t wait to see what we do next!! #ScienceWin #tenured
So excited to share our work using multi-state modeling to predict dynamic risk of CAD over the lifetime. Thanks to amazing team and mentorship @pnatarajanmd @SashaGusevPosts @g_parmigiani @MGHCVFellows ! https://t.co/QL1grnHsYU
Accurate & dynamic estimates of #lifetime #ASCVD risk may enable earlier and more effective #cvPrev Now in @NatureComms, innovative work led by @MGHHeartHealth 💫 fellow @tigerstatdoc to develop and validate MSGene: a multistate lifetime risk model for #ASCVD! @broadinstitute https://t.co/A5AO50shMc
10-year ASCVD risk prediction leads to older individuals being prioritized for statins missing opportunities for earlier risk recognition & prevention. Our work led by @tigerstatdoc uses genetics & dynamic risk factor trajectories toward intersecting risk *early.*… https://t.co/vqp6EcLSda
Huge congrats to @kevinmbio for his outstanding @harvardmed @BBS_Harvard PhD defense, and even more for all of the thoughtful, exciting and collaborative science he has led during his graduate training over the years @DanaFarber @broadinstitute - thrilled for you! https://t.co/BsoIdnsoao
#MustRead: The idea behind this study is to advance precision medicine in babies using computational modelling. https://t.co/hEUc0QCpiP